Get the Stockscreener App
16.92
0.30%
0.05
After Hours:
16.98
0.06
+0.35%
Adma Biologics Inc stock is traded at $16.92, with a volume of 1.98M.
It is up +0.30% in the last 24 hours and down -11.55% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$16.87
Open:
$16.8
24h Volume:
1.98M
Relative Volume:
0.72
Market Cap:
$4.00B
Revenue:
$382.81M
Net Income/Loss:
$68.13M
P/E Ratio:
60.43
EPS:
0.28
Net Cash Flow:
$78.82M
1W Performance:
+5.09%
1M Performance:
-11.55%
6M Performance:
+42.66%
1Y Performance:
+221.06%
1-Day Range:
$16.22
$16.97
1-Week Range:
$15.70
$17.20
52-Week Range:
$5.02
$23.64
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
16.92 | 4.00B | 382.81M | 68.13M | 78.82M | 0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add (NASDAQ:ADMA) - Seeking Alpha
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Engaging In Insider Activity, Kaitlin M. Kestenberg-Messina At ADMA Biologics Exercises Options Worth $28K - Benzinga
Will Weakness in ADMA Biologics, Inc.'s (NASDAQ:ADMA) Stock Prove Temporary Given Strong Fundamentals? - Simply Wall St
Short Interest in ADMA Biologics, Inc. (NASDAQ:ADMA) Increases By 11.8% - MarketBeat
Jim Cramer on ADMA Biologics, Inc. (ADMA): ‘I Would Wait For It To Come Down Before I Would Pull The Trigger’ - Insider Monkey
8 Stocks on Jim Cramer’s Radar - Insider Monkey
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business' - Benzinga
Where are the Opportunities in (ADMA) - Stock Traders Daily
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Inspire Investing LLC - MarketBeat
Veracity Capital LLC Boosts Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
ADMA Biologics to acquire certain assets from Biotest Pharmaceuticals Corp - Reuters
Adma Biologics (ADMA) Rises Higher Than Market: Key Facts - Yahoo Finance
Peering Into ADMA Biologics's Recent Short Interest - Benzinga
Brokers Set Expectations for ADMA Biologics FY2025 Earnings - MarketBeat
Perpetual Ltd Acquires Shares of 3,632,677 ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock? - MSN
Blood Plasma Market Growing at 4.07% CAGR to Hit 42.0 Billion USD by 2032 | Emergent BioSolutions, ADMA - EIN News
There May Still Be Time to Get in on These 3 Trending Biotechs - MarketBeat
Sana Biotechnology Inc (SANA-Q) QuotePress Release - The Globe and Mail
How the (ADMA) price action is used to our Advantage - Stock Traders Daily
Assenagon Asset Management S.A. Sells 2,882,776 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
ADMA Biologics Inc. (ADMA): Why Should You Buy This Growth Stock For The Next 5 Years? - Insider Monkey
ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Update - MarketBeat
ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by JPMorgan Chase & Co. - MarketBeat
Brokers Issue Forecasts for ADMA Biologics FY2024 Earnings - Defense World
Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why - MSN
ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.8%Here's What Happened - MarketBeat
Analysts Issue Forecasts for ADMA Biologics FY2024 Earnings - MarketBeat
GAMMA Investing LLC Buys 967 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
ADMA Biologics (NASDAQ:ADMA) Trading Down 8.8%What's Next? - MarketBeat
EWG Elevate Inc. Invests $480,000 in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update - The Manila Times
Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing - MSN
12 Best Growth Stocks Under $25 to Buy Now - Insider Monkey
Is ADMA Biologics, Inc. (ADMA) the Best Growth Stock to Buy Now Under $25? - Insider Monkey
(ADMA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? - MSN
High Growth Tech Stocks to Watch in January 2025 - Yahoo Finance
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025 - The Manila Times
ADMA Biologics, Inc. Appoints Eduardo Rene Salas to Serve on the Board as a Class I Director - Marketscreener.com
Why Is ADMA Biologics, Inc. (ADMA) Among the Best Multibagger Stocks to Buy Right Now? - Insider Monkey
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):